GPs are being expected to act as a “specialist gender service” for young people despite lacking training or experience in the ...

Theramex's GnRH antagonist Yselty (linzagolix) has been given the green light for use in women with moderate to severe symptoms caused by uterine fibroids – benign tumours that develop in the ...

Abbott and Neurocrine Biosciences have entered into a collaboration to develop and commercialize elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that has recently completed a Phase ...

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Accordingly, it is the policy of the United States that it will not fund, sponsor, promote, assist, or support the so-called ...

Mortola JF. From GnRH to SSRIs and Beyond: Weighing the Options for Drug Therapy in Premenstrual Syndrome. MedGenMed 1(2), 1999. [formerly published in Medscape Women's Health eJournal 2(5), 1997].